Non-pegylated Liposomal Doxorubicin (Myocet ®) Plus Docetaxel (Taxotere ®) (MYTAX), as First-line Chemotherapy (CHT), in Metastatic Breast Cancer (MBC): Results of a Phase II Study

被引：0
|
作者：
Imperatori, L. [1 ]
Lippe, P. [1 ]
Trapuzzano, C. [1 ]
Laici, G. [1 ]
Cappelletti, C. [1 ]
Tamburrano, T. [1 ]
Mattioli, R. [1 ]
机构：
[1] Osped Santa Croce, Fano, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71517-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [31] Phase II randomized trial of pegylated liposomal doxorubicin vs. weekly docetaxel with subsequent crossover as first-line chemotherapy for metastatic breast cancer.
    Yardley, DA
    Shipley, DM
    Greco, FA
    Montes, I
    McCarthy, M
    Hainsworth, JD
    Burris, HA
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S203 - S204
  • [32] Phase I/II Gemcitabine (G) with Pegylated Liposomal Doxorubicin (PLD) as first-line therapy in metastatic breast cancer (MBC) in Asian women
    Wong, Zee Wan
    Shah, Valencia A.
    Wong, Nan Soon
    Ang, Peter Cher Siang
    Silverman, Carrie
    Tan, Say Beng
    Cheung, Yin Bun
    Chowbay, Balram
    See, Hui Ti
    Khoo, Kei Siong
    ANNALS OF ONCOLOGY, 2004, 15 : 43 - 43
  • [33] Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer:: final results of a phase II trial
    Schmid, P
    Krocker, J
    Jehn, C
    Michniewicz, K
    Lehenbauer-Dehm, S
    Eggemann, H
    Heilmann, V
    Kümmel, S
    Schulz, CO
    Dieing, A
    Wischnewsky, MB
    Hauptmann, S
    Elling, D
    Possinger, K
    Flath, B
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1624 - 1631
  • [34] PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND WEEKLY PACLITAXEL (T) AS FIRST-LINE TREATMENT IN METASTATIC BREAST CANCER (MBC)
    Badalamenti, Giuseppe
    Valerio, Maria Rosaria
    Rinaldi, Gaetana
    Arcara, Carlo
    Cicero, Giuseppe
    Vizzini, Laura
    Travagliato, Maria Grazia
    Intrivici, Chiara
    Russo, Antonio
    Gulotta, Gaspare
    Gebbia, Nicola
    Fulfaro, Fabio
    ANNALS OF ONCOLOGY, 2004, 15 : 24 - 24
  • [35] Use of non pegylated liposomial doxorubicin (Myocet) asssociated with cyclophosphamide or docetaxel as first line treatment in metastatic breast cancer
    Livi, Lorenzo
    Meattini, Icro
    Bruni, Alessio
    Petrucci, Alessia
    Rampini, Andrea
    Mileo, Annamaria
    Paoletti, Lisa
    Sardaro, Angela
    Borghesi, Simona
    Biti, Giampaolo
    ANNALS OF ONCOLOGY, 2007, 18 : 40 - 41
  • [36] Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients
    Kurtz, J. E.
    Rousseau, F.
    Meyer, N.
    Delozier, T.
    Serin, D.
    Nabet, M.
    Djafari, L.
    Dufour, P.
    ONCOLOGY, 2007, 73 (3-4) : 210 - 214
  • [37] Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in elderly metastatic breast cancer patients
    Dufour, P. R.
    Rousseau, F.
    Meyer, N.
    Delozier, T.
    Serin, D.
    Nabet, M.
    Djafari, L.
    Kurtz, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Chemotherapy based on liposomal doxorubicin (Myocet (R)) in metastatic breast cancer after prior first-line treatment with anthracycline
    Hanslik, Jerzy
    ONCOLOGY IN CLINICAL PRACTICE, 2010, 6 : A28 - A30
  • [39] Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer
    Wong, Zee-Wan
    Ang, Peter Cher-Siang
    Chowbay, Balram
    Wong, Nan-Soon
    See, Hui-Ti
    Khoo, Kei-Siong
    BREAST, 2008, 17 (05): : 517 - 522
  • [40] Combination of docetaxel and doxorubicin as first-line chemotherapy in metastatic breast cancer
    Baltali, E
    Özisik, Y
    Güler, N
    Firat, D
    Altundag, K
    TUMORI, 2001, 87 (01) : 18 - 19
12345